CARsgen (2171.HK) reversed early gains to close at HK$10.00, down 4.21% from the prior HK$10.44, after spiking to HK$10.99 at the 09:30 open and then sliding to a HK$10.00 low at 14:47, finishing near the session bottom on a thin 0.47% turnover rate. The driver was the inclusion of satri-cel (zevorcabtagene autoleucel) in China's commercial health insurance innovative drug list, news that had already lifted the stock roughly 6% in a single session; the morning pop read as short-term profit taking, and pipeline items such as first-patient dosing for CT1190B in R/R LBCL did not extend the move. Q2 2026 revenue was HK$35.76m, up 28.08% year on year, while the net loss narrowed 6.73% to HK$38.50m and the net margin stayed at -107.66%. The shares are down 34.73% YTD, 65.03% below the HK$28.60 52-week high, and sit under both the MA20 of HK$11.045 and MA60 of HK$12.15, though volume did not show heavy distribution.